Arzerra

RSS
Withdrawn

This medicine's authorisation has been withdrawn

ofatumumab
MedicineHumanWithdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 28 February 2019, the European Commission withdrew the marketing authorisation for Arzerra (ofatumumab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Novartis Europharm Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Arzerra was granted marketing authorisation in the EU on 19 April 2010 for the treatment of chronic lymphocytic leukaemia (CLL). The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2015. 

The European Public Assessment Report (EPAR) for Arzerra is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (639.47 KB - PDF)

View

español (ES) (529.69 KB - PDF)

View

čeština (CS) (605.37 KB - PDF)

View

dansk (DA) (526.59 KB - PDF)

View

Deutsch (DE) (530.74 KB - PDF)

View

eesti keel (ET) (525.22 KB - PDF)

View

ελληνικά (EL) (645 KB - PDF)

View

français (FR) (530.34 KB - PDF)

View

hrvatski (HR) (550.17 KB - PDF)

View

italiano (IT) (525.56 KB - PDF)

View

latviešu valoda (LV) (601.3 KB - PDF)

View

lietuvių kalba (LT) (562.92 KB - PDF)

View

magyar (HU) (606.24 KB - PDF)

View

Malti (MT) (601.91 KB - PDF)

View

Nederlands (NL) (528.75 KB - PDF)

View

polski (PL) (614.43 KB - PDF)

View

português (PT) (529.49 KB - PDF)

View

română (RO) (559.74 KB - PDF)

View

slovenčina (SK) (600.96 KB - PDF)

View

slovenščina (SL) (592.67 KB - PDF)

View

Suomi (FI) (525.59 KB - PDF)

View

svenska (SV) (527.01 KB - PDF)

View

Product information

български (BG) (2.51 MB - PDF)

View

español (ES) (1.46 MB - PDF)

View

čeština (CS) (2.04 MB - PDF)

View

dansk (DA) (1.48 MB - PDF)

View

Deutsch (DE) (1.47 MB - PDF)

View

eesti keel (ET) (1.38 MB - PDF)

View

ελληνικά (EL) (2.58 MB - PDF)

View

français (FR) (1.45 MB - PDF)

View

hrvatski (HR) (1.5 MB - PDF)

View

íslenska (IS) (1.4 MB - PDF)

View

italiano (IT) (1.11 MB - PDF)

View

latviešu valoda (LV) (2.08 MB - PDF)

View

lietuvių kalba (LT) (1.15 MB - PDF)

View

magyar (HU) (2.14 MB - PDF)

View

Malti (MT) (2.22 MB - PDF)

View

Nederlands (NL) (1.55 MB - PDF)

View

norsk (NO) (1.33 MB - PDF)

View

polski (PL) (2.04 MB - PDF)

View

português (PT) (1.37 MB - PDF)

View

română (RO) (1.57 MB - PDF)

View

slovenčina (SK) (2.07 MB - PDF)

View

slovenščina (SL) (1.95 MB - PDF)

View

Suomi (FI) (1.33 MB - PDF)

View

svenska (SV) (1.52 MB - PDF)

View
Latest procedure affecting product information: II/0051
02/10/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (499.43 KB - PDF)

View

español (ES) (463.19 KB - PDF)

View

čeština (CS) (481.28 KB - PDF)

View

dansk (DA) (456.65 KB - PDF)

View

Deutsch (DE) (451.69 KB - PDF)

View

eesti keel (ET) (455.91 KB - PDF)

View

ελληνικά (EL) (538.02 KB - PDF)

View

français (FR) (456.78 KB - PDF)

View

hrvatski (HR) (516.79 KB - PDF)

View

íslenska (IS) (454.34 KB - PDF)

View

italiano (IT) (455.89 KB - PDF)

View

latviešu valoda (LV) (487.34 KB - PDF)

View

lietuvių kalba (LT) (566.09 KB - PDF)

View

magyar (HU) (474.45 KB - PDF)

View

Malti (MT) (470.85 KB - PDF)

View

Nederlands (NL) (453.25 KB - PDF)

View

norsk (NO) (454.78 KB - PDF)

View

polski (PL) (529.8 KB - PDF)

View

português (PT) (483.59 KB - PDF)

View

română (RO) (495.54 KB - PDF)

View

slovenčina (SK) (519.11 KB - PDF)

View

slovenščina (SL) (503.38 KB - PDF)

View

Suomi (FI) (458.87 KB - PDF)

View

svenska (SV) (477.82 KB - PDF)

View

Product details

Name of medicine
Arzerra
Active substance
Ofatumumab
International non-proprietary name (INN) or common name
ofatumumab
Therapeutic area (MeSH)
Leukemia, Lymphocytic, Chronic, B-Cell
Anatomical therapeutic chemical (ATC) code
L01XC10

Pharmacotherapeutic group

Monoclonal antibodies

Therapeutic indication

Previously untreated chronic lymphocytic leukaemia (CLL): Arzerra in combination with chlorambucil or bendamustine is indicated for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy.

Relapsed CLL: Arzerra is indicated in combination with fludarabine and cyclophosphamide for the treatment of adult patients with relapsed CLL.

Refractory CLL: Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.

Authorisation details

EMA product number
EMEA/H/C/001131
Marketing authorisation holder
Novartis Europharm Ltd

Frimley Business Park
Camberley GU16 7SR
United Kingdom

Marketing authorisation issued
19/04/2010
Withdrawal of marketing authorisation
28/02/2019
Revision
16

Assessment history

This page was last updated on

Share this page